Impact of bone metastases on overall survival in patients with metastatic renal cell cancer treated with sunitinib

Trial Profile

Impact of bone metastases on overall survival in patients with metastatic renal cell cancer treated with sunitinib

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Sunitinib (Primary) ; Axitinib; Everolimus; Pazopanib; Sorafenib; Temsirolimus
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top